S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:KROS

Keros Therapeutics (KROS) Stock Price, News & Analysis

$64.66
-1.45 (-2.19%)
(As of 03/27/2024 ET)
Today's Range
$59.14
$65.86
50-Day Range
$51.30
$70.48
52-Week Range
$27.02
$73.00
Volume
490,365 shs
Average Volume
461,338 shs
Market Capitalization
$2.33 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$86.00

Keros Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
33.0% Upside
$86.00 Price Target
Short Interest
Bearish
5.34% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.53mentions of Keros Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($5.11) to ($5.42) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.90 out of 5 stars

Medical Sector

424th out of 939 stocks

Pharmaceutical Preparations Industry

200th out of 422 stocks

KROS stock logo

About Keros Therapeutics Stock (NASDAQ:KROS)

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

KROS Stock Price History

KROS Stock News Headlines

Dyne Therapeutics appoints John Cox CEO
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Keros Therapeutics (NASDAQ:KROS) Shares Down 4.7%
KROS Apr 2024 30.000 put
KROS Apr 2024 70.000 put
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
KROS Apr 2024 65.000 put
KROS Apr 2024 75.000 call
KROS Mar 2024 70.000 call
KROS Jun 2024 75.000 put
KROS Sep 2024 30.000 put
KROS Sep 2024 70.000 call
See More Headlines
Receive KROS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/01/2024
Today
3/27/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KROS
Fax
N/A
Employees
136
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$86.00
High Stock Price Target
$105.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+34.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-152,990,000.00
Pretax Margin
-101,319.21%

Debt

Sales & Book Value

Annual Sales
$150,000.00
Price / Sales
15,509.78
Book Value
$11.09 per share

Miscellaneous

Free Float
25,908,000
Market Cap
$2.33 billion
Optionable
Optionable
Beta
1.28
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Jasbir S. Seehra Ph.D. (Age 68)
    President, CEO, Treasurer, & Director
    Comp: $985.58k
  • Mr. Christopher Rovaldi M.Sc. (Age 49)
    Chief Operating Officer
    Comp: $708.75k
  • Mr. Keith C. Regnante MBA (Age 54)
    Chief Financial Officer
    Comp: $603.24k
  • Ms. Esther Cho J.D.
    Senior VP, General Counsel & Secretary
  • Ms. Robin Wagner
    Senior Vice President of Human Resources
  • Mr. John Oram M.B.A.
    Senior Vice President of Program & Portfolio Management

KROS Stock Analysis - Frequently Asked Questions

Should I buy or sell Keros Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Keros Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KROS shares.
View KROS analyst ratings
or view top-rated stocks.

What is Keros Therapeutics' stock price target for 2024?

7 equities research analysts have issued twelve-month price objectives for Keros Therapeutics' shares. Their KROS share price targets range from $60.00 to $105.00. On average, they expect the company's share price to reach $86.00 in the next twelve months. This suggests a possible upside of 33.0% from the stock's current price.
View analysts price targets for KROS
or view top-rated stocks among Wall Street analysts.

How have KROS shares performed in 2024?

Keros Therapeutics' stock was trading at $39.76 at the beginning of the year. Since then, KROS shares have increased by 62.6% and is now trading at $64.66.
View the best growth stocks for 2024 here
.

When is Keros Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our KROS earnings forecast
.

How were Keros Therapeutics' earnings last quarter?

Keros Therapeutics, Inc. (NASDAQ:KROS) announced its earnings results on Friday, March, 1st. The company reported ($1.34) earnings per share for the quarter, beating analysts' consensus estimates of ($1.37) by $0.03. The business earned $0.14 million during the quarter. During the same period last year, the firm posted ($1.09) earnings per share.

What ETFs hold Keros Therapeutics' stock?

ETFs with the largest weight of Keros Therapeutics (NASDAQ:KROS) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC) and ALPS Medical Breakthroughs ETF (SBIO).BNY Mellon Innovators ETF (BKIV).

What other stocks do shareholders of Keros Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Keros Therapeutics investors own include AbbVie (ABBV), Brainstorm Cell Therapeutics (BCLI), Cloudera (CLDR), CVS Health (CVS), Inovio Pharmaceuticals (INO), Iovance Biotherapeutics (IOVA), Karyopharm Therapeutics (KPTI), Neurocrine Biosciences (NBIX), Novavax (NVAX) and Pfizer (PFE).

When did Keros Therapeutics IPO?

Keros Therapeutics (KROS) raised $75 million in an IPO on Wednesday, April 8th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

Who are Keros Therapeutics' major shareholders?

Keros Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.78%), Vanguard Group Inc. (3.98%), Braidwell LP (3.73%), Price T Rowe Associates Inc. MD (3.48%), Price T Rowe Associates Inc. MD (3.48%) and Franklin Resources Inc. (2.33%). Insiders that own company stock include Christopher Rovaldi, Claudia Ordonez, Jennifer Lachey, Julius Knowles, Keith Regnante and Richard K Prins.
View institutional ownership trends
.

How do I buy shares of Keros Therapeutics?

Shares of KROS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KROS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners